Aspects of Insulin Treatment in Uremic Insulin-Dependent Diabetic Patients before and after Active Replacement Therapy

  • Ole Schmitz
Part of the Topics in Renal Medicine book series (TIRM, volume 6)


Since intensive metabolic control and vigorous antihypertensive therapy only postpone, but do not prevent, end-stage renal failure (ESRF) in diabetics and because diabetics in many parts of the world are no longer excluded from ESRF programs, it is not surprising that a great and still increasing number of candidates for dialysis therapy and kidney transplantation consist of diabetic patients. At the moment 10%–25% of the population admitted to ESRF programs in the United States and Western Europe suffer from diabetes mellitus. Consequently, profound insight into the pathophysiology of glucose homeostasis and insulin kinetics in this complicated clinical condition is necessary to assure optimal therapy in nondialyzed, dialyzed, and recently kidney-transplanted diabetic patients. A perfect glycemic and metabolic control is obviously still the goal of therapy in these diabetics in order to reduce further morbidity in a group of patients already heavily burdened by severe complications.


Diabetic Nephropathy Continuous Ambulatory Peritoneal Dialysis Continuous Subcutaneous Insulin Infusion Dialysis Therapy Normal Kidney Function 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    DeFronzo RA, Tobin JD, Rowe J W, Andres R: Glucose intolerance in uremia: quantification of pancreatis beta cell sensitivity to glucose and tissue sensitivity to insulin. J Clin Invest 62: 425–435, 1978.PubMedCrossRefGoogle Scholar
  2. 2.
    DeFronzo RA, Alvestrand A, Smith D, Hendler R, Hendler E, Wahren J: Insulin resistance in uremia. J Clin Invest 67: 563–568, 1981.PubMedCrossRefGoogle Scholar
  3. 3.
    Smith D, DeFronzo RA: Insulin resistance in uremia mediated by postbinding defects. Kidney Int 22: 54–62, 1982.PubMedCrossRefGoogle Scholar
  4. 4.
    Schmitz O, Alberti KGMM, Christensen NJ, Hasling C, Hjollund E, Beck-Nielsen H, Orskov H: Aspects of glucose homeostasis in uremia as assessed by the hyperinsulinemic euglycemic clamp technique. Metabolism 34: 465–473, 1985.PubMedCrossRefGoogle Scholar
  5. 5.
    Schmitz O, Arnfred J, Orskov C, Nielsen OH: Uremia is characterized by impaired glucose-mediated glucose uptake and inappropriate hepatic glucose output to a.hyperglycemic challenge. (Submitted for publication), 1987.Google Scholar
  6. 6.
    McCaleb ML, Mevorach R, Freeman RB, Izzo MS, Lockwood DH: Induction of insulin resistance in normal adipose tissue by uremic human serum. Kidney Int 25: 416–421, 1984.PubMedCrossRefGoogle Scholar
  7. 7.
    Rizza RA, Mandarino LJ, Genest J, Baker BA, Gerich JE: Production of insulin resistance by hyperinsulinaemia in man. Diabetologia 28: 70–75, 1985.PubMedGoogle Scholar
  8. 8.
    Pedersen O, Schmitz O, Hjollund E, Richelsen B, Hansen HE: Postbinding defects of insulin action in human adipocytes from patients with uremia. Kidney Int 27: 780–784, 1985.PubMedCrossRefGoogle Scholar
  9. 9.
    Pedersen O, Bech-Nielsen H: Insulin resistance and type 1 (insulin-dependent) diabetes mellitus. Diabetes Care 10: 516–523, 1987.PubMedGoogle Scholar
  10. 10.
    Schmitz O: Insulin-mediated glucose uptake in non-dialyzed and dialyzed uremic insulin-dependent diabetic subjects. Diabetes 34: 1152–1159, 1985.PubMedCrossRefGoogle Scholar
  11. 11.
    Schmitz O, Alberti KGMM, Orskov H: Insulin resistance in uraemic insulin-dependent diabetics: effect of dialysis therapy as assessed by the artificial endocrine pancreas. Acta Endocrinol (Copenh) 105: 371–378, 1984.Google Scholar
  12. 12.
    Rabkin R, Ryan MP, Duckworth WC: The renal metabolism of insulin. Diabetologia 27: 351–357, 1984.PubMedCrossRefGoogle Scholar
  13. 13.
    Mondon CE, Dolkas CB, Reaven GM: Effect of acute uremia in insulin renewal by the isolated perfused rat liver and muscle. Metabolism 27: 133–142, 1978.PubMedCrossRefGoogle Scholar
  14. 14.
    Rabkin R, Unterhalter SA, Duckworth WC: Effect of prolonged uremia on insulin metabolism by isolated liver and muscle. Kidney Int 16: 433–439, 1979.PubMedCrossRefGoogle Scholar
  15. 15.
    Ferrannini E, Pilo A, Navalesi R, Citti L, Cecchetti P, Masoni A: Insulin kinetics and glucose-induced insulin delivery in chronically dialyzed subjects: acute effects of dialysis. J Clin Endicrinol Metab 49: 15–22, 1979.CrossRefGoogle Scholar
  16. 16.
    Schmitz O, Hjollund E, Alberti KGMM, Orskov H, Beck-Nielsen H: Assessment of tissue sensitivity to insulin in uraemic patients on long-term haemodialysis therapy. Diabetes Res 2: 57–63, 1985.PubMedGoogle Scholar
  17. 17.
    Avram MM, Paik SK, Okanya D, Rajpal K: The natural history of diabetic nephropathy: unpredictable insulin requirements-a further clue. Clin Nephrol 21: 36–38, 1984.PubMedGoogle Scholar
  18. 18.
    Urion D, Vreman HJ, Winer MW: Effect of acetate on hypoglycemic seizures in mice. Diabetes 28: 1022–1026, 1979.PubMedCrossRefGoogle Scholar
  19. 19.
    Schmitz O, Hansen AP, Hansen HE, Orskov H: Inhibition of arginine-and hypoglycemia-induced growth hormone release by acetate in dialyzed patients. Clin Nephrol 17: 70–76, 1982.PubMedGoogle Scholar
  20. 20.
    Hansen AaP, Orskov H, Hansen HE, Schmitz O, Posborg V, Nosadini GA, Noy GA, Alberti KGMM: Glucose control during hemodialysis of diabetic patients. J Artif Organs ISuppl] 5: 681–685, 1981.Google Scholar
  21. 21.
    Schade DS, Eaton RP, Spencer W, Goldman R, Corbett WT: The peritoneal absorption of insulin of diabetic man: a potential site for a mechanical insulin delivery system. Metabolism 28: 195–197, 1979.PubMedCrossRefGoogle Scholar
  22. 22.
    Schade DS, Eaton RP, Friedman NM, Spencer WJ: Normalization of plasma insulin profiles with intraperitoneal insulin infusion in diabetic man. Diabetologia 19:35,-39, 1980.Google Scholar
  23. 23.
    Shapiro DJ, Blumenkrantz MJ, Levin SR, Coburn J W: Absorption and action of insulin added to peritoneal dialysate in dogs. Nephron 23: 174–180, 1979.PubMedCrossRefGoogle Scholar
  24. 24.
    Janle-Swain E, Thornhill JA, Carter JM, Hinsman I, Jackson H, Swain SL, Ash SR: Improvement in kidney function with continuous intraperitoneal insulin infusion (CIPII) in severe diabetic glomerulopathy. Diabetic Nephropathy 2: 16–22, 1983.Google Scholar
  25. 25.
    Stephen RL, Maxwell JG, Kablitz C, Jacobsen SC, Hanover B, Tyler F: Intraperitoneal insulin regimens and diabetic nephropathy. In: Davison AM, Guillou PJ (eds) Proceedings of the European Dialysis and Transplant Association-European Renal Association, vol 20. London: Pitman, 1983, pp 692–699.Google Scholar
  26. 26.
    Johnson CA, Amidon G, Reichert JE, Porter WR: Absorption of insulin to the surface of peritoneal dialysis solution containers. Am J Kidnery Dis 3: 224–228, 1983.Google Scholar
  27. 27.
    Wideröe T-E, Smeby LC, Berg KJ, Jörstad S, Svartâs TM: intraperitoneal (1251) insulin absorption during intermittent and continuous peritoneal dialysis. Kidney Int 23: 22–28, 1983.PubMedCrossRefGoogle Scholar
  28. 28.
    Rottembourg J, Issad B, Poignet JL, Strippoli P, Balducci A, Slama G, Gahl GM: Residual renal function and control of blood glucose levels in insulin-dependent diabetic patients treated by CAPD. In: Keen H, Legrain M (eds) Prevention and treatment of diabetic nephropathy. Lancaster UK: MTP Press, 1983, pp 339–352.Google Scholar
  29. 29.
    Schmitz O, Sorensen SS, Alberti KGMM, Orskov H, Hansen HE: Metabolic control in newly kidney transplanted type 1 diabetics: ‘normalization’ by insulin pump treatment (CSII). J Diabetic Complications (in press), 1987.Google Scholar

Copyright information

© Springer Science+Business Media Dordrecht 1988

Authors and Affiliations

  • Ole Schmitz

There are no affiliations available

Personalised recommendations